FindTrial
Sign In

Grafalon 20 mg/ml concentrato per soluzione per infusione

DRUG3 trials

Sponsors

IRCCS Istituto Giannina Gaslini, Fundacion Canaria Instituto De Investigacion Sanitaria De Canarias, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Conditions

Acute Myeloid Leukemia (AML)Know in a controlled and randomized clinical trialPatient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levelsafter two years of post-transplant follow-up.as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant.carried out in low-risk patients immunological and stable renal functiondetected in the third month post-transplant

Phase 2

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING Study
Not yet recruitingCTIS2024-519895-23-00
Fundacion Canaria Instituto De Investigacion Sanitaria De Canariasafter two years of post-transplant follow-up., as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., carried out in low-risk patients immunological and stable renal function +5
Target: 80Updated: 2025-01-29
Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)
Not yet recruitingCTIS2024-520326-11-00
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di BresciaAcute Myeloid Leukemia (AML)
Target: 82Updated: 2025-01-31
TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neuroblastoma
RecruitingCTIS2024-519089-32-02
IRCCS Istituto Giannina GasliniPatient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.
Start: 2023-08-29Target: 19Updated: 2025-01-31